The kidney and cardiovascular risk--implications for management: a consensus statement from the European Society of Hypertension (Q36871027)

16 August 2017

1 reference

title

The kidney and cardiovascular risk--implications for management: a consensus statement from the European Society of Hypertension (English)

1 reference

16 August 2017

George S Stergiou

6

0 references

Luis Miguel Ruilope

object named as

Luis Ruilope

1

0 references

Giuseppe Mancia

4

object named as

Giuseppe Mancia

1 reference

16 August 2017

2

Sverre E Kjeldsen

1 reference

16 August 2017

Alejandro de la Sierra

3

1 reference

16 August 2017

Piero Ruggenenti

5

1 reference

16 August 2017

George L Bakris

7

1 reference

16 August 2017

Thomas D Giles

8

1 reference

16 August 2017

1 January 2007

1 reference

16 August 2017

1 reference

16 August 2017

16

1 reference

16 August 2017

2

1 reference

16 August 2017

72-79

1 reference

Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement

16 August 2017

1 reference

https://api.crossref.org/works/10.1080%2F08037050701338985

Evidence-based medicine in hypertension: what type of evidence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050701338985

Chronic kidney disease as a situation of high added risk in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050701338985

Renal function: the Cinderella of cardiovascular risk profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050701338985

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050701338985

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050701338985

2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050701338985

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050701338985

Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050701338985

ACE inhibitors and appearance of renal events in hypertensive nephrosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050701338985

Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050701338985

Implications of albuminuria on kidney disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050701338985

Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050701338985

Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050701338985

Effects of combination treatment with losartan and trandolapril on office and ambulatory blood pressures in non-diabetic renal disease: a COOPERATE-ABP substudy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050701338985

Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050701338985

Aldosterone blockade: an emerging strategy for abrogating progressive renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050701338985

Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050701338985

Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050701338985

Development of chronic kidney disease and cardiovascular prognosis in essential hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050701338985

New-onset diabetes and antihypertensive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050701338985

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050701338985

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050701338985

Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050701338985

Preventing microalbuminuria in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050701338985

Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050701338985

The DIabetic Retinopathy Candesartan Trials (DIRECT) Programme, rationale and study design

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050701338985

Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050701338985

Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050701338985

The metabolic syndrome and chronic kidney disease in U.S. adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050701338985

Prehypertension is associated with insulin resistance state and not with an initial renal function impairment. A Metabolic Syndrome in Active Subjects in Spain (MESYAS) Registry substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050701338985

The prediabetic problem: development of non-insulin-dependent diabetes mellitus and related abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050701338985

Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: The Hoorn Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050701338985

Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050701338985

Subclinical states of glucose intolerance and risk of death in the U.S.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050701338985

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050701338985

Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050701338985

Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050701338985

Blood Pressure Predicts Risk of Developing End-Stage Renal Disease in Men and Women

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050701338985

Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050701338985

Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050701338985

10.1080/08037050701338985

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference